1. Home
  2. CXM vs ANAB Comparison

CXM vs ANAB Comparison

Compare CXM & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprinklr Inc.

CXM

Sprinklr Inc.

HOLD

Current Price

$5.48

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$66.39

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXM
ANAB
Founded
2009
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
CXM
ANAB
Price
$5.48
$66.39
Analyst Decision
Hold
Buy
Analyst Count
8
12
Target Price
$8.28
$71.67
AVG Volume (30 Days)
3.7M
634.0K
Earning Date
06-03-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.02
EPS
0.02
N/A
Revenue
$857,200,000.00
$234,603,000.00
Revenue This Year
$2.52
N/A
Revenue Next Year
$4.94
$52.14
P/E Ratio
$275.00
N/A
Revenue Growth
7.64
157.01
52 Week Low
$4.72
$17.11
52 Week High
$9.40
$73.30

Technical Indicators

Market Signals
Indicator
CXM
ANAB
Relative Strength Index (RSI) 58.79 60.48
Support Level $5.14 $52.32
Resistance Level $5.60 $68.22
Average True Range (ATR) 0.19 3.78
MACD 0.05 0.61
Stochastic Oscillator 82.21 75.87

Price Performance

Historical Comparison
CXM
ANAB

About CXM Sprinklr Inc.

Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale, all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights, and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: